EUVIMEDObjevte EUVIMED
Crossref

Impact of Pre‐Transplant Anticoagulant and Antiplatelet Use on Allograft Outcomes Following Kidney Transplant

Kelly Lavery, Andrew Santeusanio iD, Ron Shapiro, Alan Benvenisty

Clinical Transplantation · 2026-03 · 40 (3)

DOI: 10.1111/ctr.70496 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2026-03-02. Written by Kelly Lavery and 3 co-authors. Institution: Department of Pharmacy, Mount Sinai Hospital, New York, New York, USA. Major MEDLINE topics: Kidney Transplantation, Graft Survival, Anticoagulants, Platelet Aggregation Inhibitors. 14 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

Patients presenting for kidney transplantation on antithrombotic therapy may face an increased risk of bleeding and surgery‐related morbidity. How to best optimize pre‐operative antithrombotic therapies to decrease the risk for allograft complications has not been fully elucidated.

Methods

This was a single‐center, retrospective study of adult patients undergoing kidney transplantation between 2018–2024. Patients taking oral anticoagulants or antiplatelet therapies at the time of organ offer were compared to control patients not on antithrombotics. A subgroup analysis was also performed, comparing patients on warfarin versus apixaban. The primary endpoint was combined patient and allograft survival at 6 months post‐transplant. Key secondary endpoints included the incidence of delayed allograft function, blood product requirements and re‐operation, and estimated glomerular filtration rate.

Results

27 patients on anticoagulants and 26 patients on antiplatelet therapies were compared to 227 controls. No significant differences were observed in allograft survival between anticoagulant (96.3%), antiplatelet (88.5%), and control (93.4%) groups. Patients on anticoagulants exhibited a higher incidence of bleeding complications including increased blood product requirements (2.0 vs. 0.6; p < 0.01) and re‐operation (14.8% vs. 4.4%; p = 0.04) relative to controls, although this did not impact allograft function. No differences were observed in survival or bleeding endpoints between patients on warfarin and apixaban.

Conclusion

Use of anticoagulant but not antiplatelet therapy prior to transplantation was associated with an increased risk of bleeding complications, without adversely affecting short‐term allograft function. These results suggest that anticoagulant and antiplatelet therapies may be continued until the time of organ offer in select patients, and apixaban may be a suitable alternative to warfarin for patients on the transplant waiting list.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGraft SurvivalAnticoagulantsPlatelet Aggregation InhibitorsGraft RejectionPostoperative ComplicationsKidney Failure, ChronicPreoperative CareHumansFemaleRetrospective StudiesMaleMiddle AgedFollow-Up StudiesGlomerular Filtration RatePrognosisRisk FactorsKidney Function TestsAdultSurvival Rate

Author keywords

anticoagulantsapixabanhemorrhagekidney transplantationwarfarin

Substances

AnticoagulantsPlatelet Aggregation Inhibitors

Authors and institutions

  • Department of Pharmacy, Mount Sinai Hospital, New York, New York, USA.
  • Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.

ORCID profiles: Andrew Santeusanio

Cite

APA

Lavery, K., Santeusanio, A., Shapiro, R., & Benvenisty, A. (2026). Impact of Pre‐Transplant Anticoagulant and Antiplatelet Use on Allograft Outcomes Following Kidney Transplant. Clinical Transplantation, 40(3). https://doi.org/10.1111/ctr.70496

Vancouver

Lavery K, Santeusanio A, Shapiro R, Benvenisty A. Impact of Pre‐Transplant Anticoagulant and Antiplatelet Use on Allograft Outcomes Following Kidney Transplant. Clinical Transplantation. 2026;40(3). doi:10.1111/ctr.70496

BibTeX
@article{Lavery2026,
  author = {Lavery, Kelly and Santeusanio, Andrew and Shapiro, Ron and Benvenisty, Alan},
  title = {Impact of Pre‐Transplant Anticoagulant and Antiplatelet Use on Allograft Outcomes Following Kidney Transplant},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {3},
  doi = {10.1111/ctr.70496}
}
Start for free →